Tvardi Therapeutics, Inc. Common Stock (TVRD)

• Market cap: $240M
• 1 day: -1.69%
• 5 days: -3.36%
• 1 month: 422.65%
• 3 months: 408.13%
• 6 months: 526.16%
• Year to date: 377.80%
• 1 year: 180.81%
• 5 years: -86.48%
• 10 years: -78.70%
• Sector: Healthcare
• Industry: Biotechnology

About: Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

58% more capital invested

Capital invested by funds: $4.17M [Q3] → $6.59M (+$2.42M) [Q4]

41% less funds holding

Funds holding: 70 [Q3] → 41 (-29) [Q4]

82% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 34

97% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 33

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $2K

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $39 52% upside
• Avg. target: $39 52% upside
• High target: $39 52% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Jones Trading Debanjana Chatterjee 43% 1-year accuracy 3 / 7 met price target

52% upside $39

Buy Initiated

28 Apr 2025